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INTRODUCTION 
 
 
Oesophageal cancer is unique among the gastrointestinal tract malignancies 
because it embodies two distinct histopathologic types, squamous cell carcinoma 
and adenocarcinoma.(Fig. 1).  Which type of cancer occurs in a given patient or 
predominates in a given geographic area depends on many variables, including 
individual lifestyle, socioeconomic pressures, and environmental factors. The 
United States, along with many other Western countries, has witnessed in recent 
decades a profound increase in incidence rates of adenocarcinoma, whereas 
squamous cell carcinoma continues to predominate worldwide, particularly in 
India(1,2,3).. Although it would seem appropriate to individualize treatment of 
these tumors, often they are managed as a single entity(4) . A more thorough 
understanding of nature and types of surgery and its successes and failures will 
hopefully spawn a new era of therapy effectively targeting both adenocarcinoma 
and squamous cell carcinoma of the oesophagus. 
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EPIDEMIOLOGY  
Table. 1 Trends in age-adjusted incidence rates for Oesophageal cancer in India.
 
ETIOLOGIC FACTORS AND PREDISPOSING CONDITIONS  
Squamous cell carcinoma and adenocarcinoma of the oesophagus share some risk 
factors, whereas other risk factors are specific to one histologic type or the other. 
Tobacco and Alcohol Use 
Tobacco and alcohol use are considered the major contributing factors in the 
development of oesophageal cancer worldwide. It is estimated that up to 90% of the 
risk of squamous cell carcinoma of the oesophagus in India be attributed to tobacco 
and alcohol use.5 Population-based studies demonstrate that tobacco and alcohol 
use are independent risk factors and their effects are multiplicative, as evidenced by 
the association of the highest risk of developing oesophageal cancer with heavy use 
of both agents. Approximately 65% of squamous cell carcinomas of the oesophagus 
have been attributed to smoking tobacco for longer than 6 months.  Cigarette 
smoking is also a risk factor in the development of adenocarcinoma of the 
oesophagus, leading to a twofold increase in risk for heavy smokers (more than one 
pack per day).7,8 Although the effect is less for adenocarcinoma than for squamous 
cell carcinoma, quitting smoking does not appear to decrease the risk of 
adenocarcinoma, which remains elevated for decades after smoking cessation.  
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The consumption of alcoholic beverages is a major contributing factor in the 
increased risk of oesophageal squamous cell carcinoma in Western countries. A 
dose-response relationship exists between the amount of alcohol ingested and the 
risk of developing squamous cell carcinoma, and the benefit of cessation of 
drinking alcohol varies in specific geographic areas.9,10 Although specific 
carcinogens may be present in a variety of alcoholic beverages, in all likelihood it is 
alcohol itself, either as a mechanical irritant, promoter of dietary deficiency, or 
contributor to susceptibility to other carcinogens, that leads to carcinogenesis.  
Diet and Nutrition 
For both squamous cell carcinoma and adenocarcinoma of the oesophagus, case-
control studies provide evidence of a protective effect of fruits and vegetables, 
especially those eaten raw.7,11 These food groups contain a number of 
micronutrients and dietary components such as vitamins A, C, and E, selenium, 
carotenoids, and fiber that may prevent carcinogenesis. Deficiencies of the 
aforementioned nutrients and dietary components have been associated with 
increased risk of oesophageal squamous cell carcinoma in some parts of the world.  
Socioeconomic Status 
Low socioeconomic status as defined by income, education, or occupation is 
associated with increased risk for oesophageal squamous cell carcinoma and, to a 
lesser degree, for adenocarcinoma.  
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Obesity 
Increased body mass index is a risk factor for adenocarcinoma of the oesophagus, 
and individuals with the highest body mass index have up to a sevenfold greater risk 
of oesophageal cancer than those with a low body mass index.7,16,17,18 The 
mechanism by which obesity contributes to an increased risk of oesophageal 
adenocarcinoma is uncertain, although the linkage between obesity and gastro-
oesophageal reflux disease is presumed to be a chief, but not the sole, factor. 
Because of the influence of nutritional and socioeconomic factors, the risk of 
squamous cell carcinoma of the oesophagus increases with decreasing body mass 
index.   
Gastrooesophageal Reflux Disease 
Gastrooesophageal reflux disease has been implicated as one of the strongest risk 
factors for the development of adenocarcinoma of the oesophagus.19,20 Chronic 
reflux is associated with Barrett's oesophagus, the premalignant precursor of 
oesophageal adenocarcinoma. 
Helicobacter Pylori Infection 
Infection with Helicobacter pylori and particularly with cagA+ strains is inversely 
associated with the risk of adenocarcinoma of the oesophagus.  
Barrett's oesophagus 
 A diagnosis of Barrett's oesophagus confers a 40- to 125-fold higher risk of 
progressing to oesophageal carcinoma compared with the risk in the general 
11 
 
population and is the single most important risk factor for developing 
adenocarcinoma.25,26 The absolute risk that any single patient with Barrett's 
oesophagus will develop adenocarcinoma in a year is approximately 1 in 200 
(absolute risk, 0.5% per patient-year).26,27,28,29  
Tylosis 
 Patients with this condition exhibit abnormal maturation of squamous cells and 
inflammation within the oesophagus and are at extremely high risk of developing 
oesophageal cancer.  
Plummer-Vinson/Paterson-Kelly Syndrome 
Approximately 10% of individuals with Plummer-Vinson/Paterson-Kelly syndrome 
develop hypopharyngeal or oesophageal epidermoid carcinomas. The mechanisms 
by which these tumors arise have not been fully defined, although nutritional 
deficiencies as well as chronic mucosal irritation from retained food particles at the 
level of the webs may contribute to the pathogenesis of these neoplasms.  
Caustic Injury 
Squamous cell carcinomas may arise in lye strictures, often developing 40 to 50 
years after caustic injury. The majority of these cancers are located in the middle 
third of the oesophagus.  
Achalasia 
Achalasia is an idiopathic oesophageal motility disorder characterized by increased 
basal pressure in the lower oesophageal sphincter, incomplete relaxation of this 
12 
 
sphincter after deglutition, and aperistalsis of the body of the oesophagus. A 16- to 
30-fold increase in oesophageal cancer risk has been noted in achalasia patients. 
Human Papillomavirus Infection 
Several studies suggest that human papillomavirus (HPV) infection may contribute 
to the pathogenesis of oesophageal squamous cell cancers in high-incidence areas in 
Asia and South Africa. This oncogenic virus, which has been associated with 
cervical and oropharyngeal cancers, encodes two proteins (E6 and E7) that 
sequester the Rb and p53 tumor suppressor gene products.. 
Prior Aerodigestive Tract Malignancy 
Carcinomas of the aerodigestive tract arise as a consequence of multistep processes 
in cancerization fields. Patients with upper aerodigestive tract cancers develop 
second primary cancers at a rate of approximately 4% per year. Nearly 10% of 
secondary neoplasms arising in patients with prior histories of oropharyngeal 
carcinoma arise in the oesophagus. Levi et al. observed that approximately 10% of 
second primary cancers in patients with prior histories of lung carcinoma arose in 
the oesophagus. The increased risk of second primary tobacco-related carcinomas 
warrants close surveillance of patients with histories of aerodigestive tract 
malignancy. 
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APPLIED ANATOMY AND HISTOLOGY  
Anatomy 
The oesophagus bridges three anatomic compartments: the neck, thorax, and 
abdomen. The oesophagus extends from the cricopharyngeus muscle at the level of 
the cricoid cartilage to the gastrooesophageal junction(Fig. 2)31. The borders of the 
cervical oesophagus are the cricopharyngeus to the thoracic inlet (approximately 18 
cm from the incisors). The remainder of the oesophagus is commonly divided into 
thirds, with the upper third extending from the thoracic inlet to the carina 
(approximately 24 cm from the incisors), the middle third extending from the carina 
to the inferior pulmonary veins (32 cm from the incisors), and the distal oesophagus 
traversing the remaining distance into the abdomen to the gastrooesophageal 
junction (40 cm from the incisors)(Fig. 3). Squamous cell carcinoma of the 
oesophagus is the predominant histology in the cervical oesophagus and upper and 
middle thirds of the thoracic oesophagus, whereas adenocarcinoma predominates in 
the distal oesophagus. 
 
Refer Fig 3.  Anatomy of oesophagus 
Knowledge of the lymphatic drainage of the oesophagus is critical to understanding 
how the numerous surgical approaches for oesophageal cancer have evolved and 
explains why some surgeons recommend a specific procedure based on tumor 
location in the oesophagus tumors of the cervical and upper third of the thoracic 
14 
 
oesophagus drain to cervical and superior mediastinal lymph nodes. Tumors of the 
middle third of the oesophagus drain both cephalad and caudad with lymph nodes at 
risk in the paratracheal, hilar, subcarinal, perioesophageal, and pericardial nodal 
basins. Lesions in the distal oesophagus primarily drain to lymph nodes in the lower 
mediastinum and celiac axis region (Fig. 4 ). Due to the extensive lymphatic 
network and rich mucosal and submucosal lymphatics within the wall of the 
oesophagus, skip metastases for upper third lesions have been noted in celiac axis 
nodal basins, and likewise, cervical lymph node metastases have been noted in as 
many as 30% of patients with distal oesophageal lesions. This forms the basis for 
some surgeons' recommendation of a more thorough oncologic procedure, a 
combined transthoracic and abdominal approach for lesions of the mid- and distal 
oesophagus,31,32 and for others' recommendation of a three-field (cervical, 
mediastinal, and abdominal) lymphadenectomy for all tumors of the mid- through 
distal oesophagus.32,33 However, lymphatic spread correlates with pathologic T 
category of the primary oesophageal tumor, and lymph node metastases are initially 
limited in an overwhelming majority of patients to regional lymph nodes. Lymph 
node involvement in lymphatic basins distant from the primary tumor are rarely 
identified unless metastases to regional lymph nodes have already occurred. These 
data challenge the validity of extensive lymphadenectomy and also suggest the 
potential value of sentinel lymph node sampling to direct surgical dissection.  
Refer Fig. 4. Lymphatic drainage of oesophagus 
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HISTOLOGY 
The overwhelming majority of oesophageal malignancies may be classified as 
either squamous cell carcinomas or adenocarcinomas. Squamous cell carcinomas 
account for majority of oesophageal malignancies diagnosed in the India(Fig. 5)  . 
Approximately 60% of these neoplasms are located in the middle third of the 
oesophagus, whereas 30% and 10% arise in the distal third and proximal third of the 
intrathoracic oesophagus, respectively.32,33 Typically, these tumors are associated 
with contiguous or noncontiguous carcinoma in situ as well as widespread 
submucosal lymphatic dissemination.35,36  
 
Refer. Fig. 5 Squamous cell carcinomas showing epithelisation, inter cellular  
bridges and cytokeratin 
Adenocarcinomas frequently arise in the context of Barrett's oesophagus; because of 
this, these tumors tend to be localized in the distal third of the oesophagus and may 
be fungating or stenotic in appearance.(Fig 7,9,10,)38,39. The vast majority of the 
tumors are associated with intestinal metaplasia or dysplasia. No significant 
survival differences have been noted in adenocarcinoma patients compared with 
individuals with similarly staged squamous cell cancers.41,42  
 
Refer. Fig. 6. Adenocarcinoma 
Several rare cancers of the oesophagus have been described, including squamous 
cell carcinoma with sarcomatous features, as well as adenoid cystic and 
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mucoepidermoid carcinomas.43,44,45,46,47 These neoplasms are indistinguishable 
clinically and prognostically from the more common types of oesophageal 
carcinoma. 
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ORIGIN OF STUDY 
In the absence of medical contradications for surgery, resection remains the main 
stay of treatment for localized oesophageal cancer even upto stage IV A, but overall 
5 year survival remains disappointing which is less than 25% , but still this survival 
rate is superior to other modalities like chemo-radiation. The pros and cons of 
various surgical procedures like Trans-hiatal oesophagectomy and IVOR-LEWIS 
operation are discussed in this paper.  
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
REVIEW OF LITERATURE 
NATURAL HISTORY AND PATTERNS OF FAILURE  
Natural history data and patterns of failure after specific treatment modalities 
provide insight into the biologic tendencies of oesophageal carcinoma and suggest 
potential therapeutic avenues to explore. At presentation, the overwhelming 
majority of patients have locally or regionally advanced or disseminated cancer, 
irrespective of histologic type. The lack of a serosal envelope and the rich 
submucosal lymphatic network of the oesophagus provide a favorable milieu for 
extensive local infiltration by tumor and lymph node involvement. If distant disease 
is not clinically evident at the time that patients are initially diagnosed with 
oesophageal carcinoma, evidence suggests that occult micrometastases are 
invariably present, and recurrence patterns confirm that distant failure is a 
significant and universally fatal component of relapse. The lung, liver, and bone are 
the most common sites of distant disease with depth of tumor invasion and lymph 
node involvement predictive of tumor dissemination. 
Refer. Table. 2. Surgery vs surgery and chemotherapy showing increased 
mortality with increased survival in surgery and chemotherapy receiving 
patients. 
Median survival after esophagectomy for patients with localized disease is 15 to 18 
months with a 5-year overall survival rate of 20% to 25%. Patterns of failure after 
esophagectomy suggest that both location of tumor and histologic type may 
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influence the distribution of recurrence. In patients with cancers of the upper and 
middle thirds of the oesophagus, which are predominately squamous cell 
carcinomas, local-regional recurrence predominates over distant recurrence, 
whereas in patients with lesions of the lower third, where adenocarcinomas are 
more frequently located, distant recurrence is more common. Although one of the 
rationales for a three-field lymph node dissection for oesophageal cancer is 
evidence of metastases in up to 30% of cervical lymph nodes, only a very small 
percentage of patients (fewer than 5%) develop clinically evident recurrence at 
cervical sites.  
Refer. Table. 3. Surgery vs surgery and radiotherapy showing better survival 
and less mortality in surgery alone patients. 
The addition of chemotherapy, radiotherapy, or chemoradiotherapy to surgery may 
alter patterns of failure, although reported results are not consistent. Preoperative 
radiotherapy and preoperative chemoradiotherapy may reduce the rate of local-
regional recurrence but has no obvious effect on the rate of distant metastases. In 
two prospective randomized trials of preoperative chemotherapy plus surgery 
versus surgery alone, one study showed a slight but non statistically significant 
decrease in distant relapse with chemotherapy (Table.2), whereas the other 
demonstrated equivalent distant recurrence rates in both the preoperative 
chemotherapy and surgery-alone arms. Similarly addition of preoperative 
radiotherapy is also of not much advocated in many trials.(Table.3) Treatment 
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failure patterns after definitive chemoradiotherapy without surgical resection reveal 
that concurrent administration of chemotherapy and radiotherapy provides better 
local control than radiotherapy alone but that distant recurrence was not 
significantly affected and was the major contributor to death.(Table 9.) Although 
the addition of surgery further reduces local failure from 45% to 32%. These 
patterns of relapse suggest that any further improvement in overall outcome for 
patients with oesophageal cancer will be achieved through advances in surgical 
techniques. 
CLINICAL PRESENTATION  
The symptoms most commonly associated with oesophageal cancer are dysphagia 
and weight loss. Unfortunately, in most instances dysphagia signifies locally 
advanced disease or distant metastases or both. At presentation, patients usually 
describe progressive dysphagia, with difficulty initially in swallowing solids, then 
liquids, and, in the most extreme circumstances, their own saliva. Taking into 
account that cure is an unlikely end result with even the most aggressive forms of 
treatment, palliation of this single symptom impacts most on the patient's quality of 
life. Other symptoms and patient demographic characteristics are closely aligned 
with the underlying histology. Patients with squamous cell carcinoma of the 
oesophagus more often are of  low socioeconomic class, and have a history of 
tobacco or alcohol abuse or both. Substantial weight loss accompanying dysphagia 
is seen in approximately 90% of patients with squamous cell carcinoma. Patients 
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with adenocarcinoma of the oesophagus tend to be males from middle to upper 
socioeconomic classes who are overweight, have a history of symptomatic gastro 
oesophageal reflux, and have been treated with antireflux therapy. 
Approximately 20% of patients experience odynophagia. Additional presenting 
symptoms may include dull retrosternal pain resulting from invasion of mediastinal 
structures, bone pain secondary to bone metastases, and cough or hoarseness 
secondary to paratracheal nodal or recurrent laryngeal nerve involvement. These 
types of symptoms suggest unresectable locally advanced disease or metastases. 
Unusual presentations are pneumonia secondary to trachea esophageal fistula or 
exsanguinating hemorrhage due to aortic invasion. 
DIAGNOSTIC STUDIES AND PRETREATMENT STAGING  
Patients who present with symptoms suggestive or pathognomic of cancer of the 
oesophagus should undergo upper endoscopy to determine whether a mass is 
present, and biopsy to establish a tissue diagnosis. A focused history taking should 
elicit information on predisposing factors for oesophageal cancer, including tobacco 
use, alcohol use, symptomatic reflux, diagnosis of Barrett's oesophagus, and history 
of head and neck malignancy. Prior surgery on the stomach or colon should be 
documented because it may influence the choice of reconstructive conduit to restore 
alimentary continuity at the time of oesophagectomy. Findings on physical 
examination that would prompt further diagnostic testing or tissue sampling include 
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hoarseness due to recurrent laryngeal nerve involvement, cervical or supraclavicular 
lymphadenopathy, pleural effusion, and new onset of bone pain. 
Refer. Fig. 7 Barium swallow study showing irregular tapering borders. 
Routine chest radiography should be performed (Fig.8). Oesophagogastroscopy 
allows precise evaluation of the extent of oesophageal and gastric involvement and 
can precisely measure the distance of the tumor from the incisors to appropriately 
categorize the tumor's location. Upper endoscopy also allows identification of 
malignant lesions or second primaries as well as indicating the presence and extent 
of Barrett's oesophagus(Fig.10) . In addition, dilation of a stenotic lesion visualized 
at endoscopy may provide relief, albeit temporarily, from dysphagia. In the event 
the strictured area cannot be successfully dilated at endoscopy, a barium swallow 
test(Fig.7) can provide information regarding extent of disease. Bronchoscopy 
should be reserved for those patients with tumors of the mid- and upper oesophagus 
to rule out invasion of the membranous trachea and possible tracheo- oesophageal 
fistula. In the absence of symptoms, bone scans should not be part of the routine 
workup because their yield is extremely low. 
Refer. Fig. 10. Upper oesophagogastroduodenoscopy showing irregular 
polypoidal lesions in various positions of oesophagus. 
On completion of the initial diagnostic workup and after a tissue diagnosis of 
oesophageal cancer, pretreatment staging procedures are essential to accurately 
determine the depth of oesophageal wall penetration, the status of regional lymph 
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node basins, and the presence or absence of distant metastases so that patients can 
be guided to the appropriate treatment options and provided with prognostic 
information. All patients should undergo a computed tomography (CT) scan of the 
chest, abdomen, and pelvis as the initial evaluation for extent of disease. CT scans 
are highly accurate (approaching 100%) in detecting liver or lung metastases and 
suggesting peritoneal carcinomatosis (ascites, omental infiltration, peritoneal tumor 
studding, etc.).  Accuracy for detecting aortic involvement or tracheobronchial 
invasion exceeds 90%. Because of this, initial staging by CT renders further, more 
costly staging studies unnecessary and avoids consideration of patients with obvious 
metastatic disease for resection. CT is inaccurate in determining T stage, because it 
cannot define individual layers of the oesophageal wall and will miss small T1 and 
T2 tumors. CT assessment of regional or distant lymph nodes is hindered by 
relatively low sensitivity (50% to 70%) due to its reliance on size criteria (larger 
than 1 cm) alone.48,49,50,51,52,53,54,55. Because lymph node involvement is 
frequently seen in small or normal-size lymph nodes, the false-negative rate is high, 
and despite a reasonable specificity of 85%, accuracy in determining lymph node 
involvement is limited (approximately 60%). 
Endoscopic ultrasonography (EUS) (Fig.11) and EUS-guided fine-needle aspiration 
(FNA) are now considered to be invaluable tools for accurate pretreatment staging 
of oesophageal cancer (Fig 11) . The accuracy of EUS in determining both T and N 
stage is a function of its ability to clearly delineate the multiple layers of the 
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oesophageal wall and its reliance on multiple criteria, including shape, border 
pattern, echogenicity, and size, to determine lymph node involvement. Numerous 
studies have demonstrated that EUS is superior to CT in both T and N staging of 
Oesophageal cancer.65,66 In these studies the overall accuracy for T staging is 
approximately 85% and for N staging is approximately 75%. The accuracy of 
determining lymph node involvement has been increased with the use of linear-
array EUS with a channel that allows passage of a needle to perform tissue 
aspiration for cytology. Studies of EUS FNA report an overall accuracy of 85% to 
100% with sensitivity and specificity of more than 90%. EUS is as accurate as CT 
in identifying aortic invasion and can detect distant metastases to lung, liver, and 
peritoneum (ascites, omental implantation, etc.) but with less accuracy than CT. 
EUS is highly operator dependent with regard to procurement of adequate images 
and correct interpretation. EUS is also limited in its ability to define relatively 
superficial lesions as either T1 or T2.56,57,58,59,60,61,62,63.  
Refer. Fig. 11 Endoscopic ultrasonogram showing five layers . 
Making this distinction is critical because it may allow the use of minimal resection 
techniques for T1 lesions and avoidance of potentially toxic preoperative 
chemoradiotherapy for both T1 and T2 tumors. To address this issue, miniprobe 
high-frequency (20-MHz) sonographic catheters that can be passed through the 
working channel of the standard endoscope are now being used and provide 
improved accuracy.64,65. A new generation of endoscopes that are thin caliber and 
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can be passed over a guidewire can traverse almost all obstructing lesions, allowing 
EUS assessment for proper staging. Although it is a relatively recent addition to the 
armamentarium of staging procedures for oesophageal cancer, 
[18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) is being 
widely used, both appropriately and inappropriately, in the management of 
oesophageal cancer. The accuracy of FDG-PET in assessing regional lymph nodes 
falls somewhere between the low and high accuracy of CT and EUS, respectively, 
and therefore its value in this respect is uncertain.  This translates into the detection 
of unsuspected metastatic disease (up-staging) in approximately 15% of patients 
and refutation of suspected disease (down-staging) in 10%, which leads to alteration 
of the intended treatment plan in at least 20% of patients. FDG-PET appears to have 
some value in evaluating response to chemotherapy and radiotherapy. Minimally 
invasive surgical techniques (laparoscopy, thoracoscopy, or both) are being used for 
staging of both local-regional and distant disease. Performing laparoscopy as the 
initial procedure at the time of planned esophagectomy adds little in the way of time 
and cost to the procedure and allows detection of unsuspected distant metastases, 
which spares the morbidity of laparotomy in 10% to 15% of cases. Luketich et al.,in 
a study comparing staging laparoscopy and thoracoscopy with CT and EUS in 53 
patients with oesophageal cancer, demonstrated either up-staging or down-staging 
in 32% when the combined laparoscopic and thoracoscopic technique was used. 
The same group from the University of Pittsburgh, using minimally invasive staging 
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techniques to assess the utility of FDG-PET scans, noted that minimally invasive 
techniques were superior, showing greater sensitivity than FDG-PET. Krasna et al. 
reported improved accuracy in evaluating local invasion, lymph node metastases, 
and distant metastases with thoracoscopic and laparoscopic staging. 
Refer. Fig. 12 Video-assisted thoracoscopy (V.A.T)  
 Although these studies suggest improved pretreatment staging with the minimally 
invasive surgical approaches, such approaches have not been embraced as standard 
staging procedures by most surgeons due to the morbidity, length of hospital stay, 
and cost associated with what is considered an additional procedure. 
Pathologic Staging  
The guidelines established by the American Joint Committee on Cancer for staging 
of oesophageal cancer are outlined in Table.4 and Table.5. 75 The primary tumor 
(T) stage is based on depth of tumor invasion into and through the wall of the 
oesophagus. The nodal (N) stage is determined by the presence of involved regional 
lymph nodes. The designation of a lymph node as regional is based on its 
relationship to the location of the primary tumor. For primary tumors located in the 
distal oesophagus, celiac lymph node involvement is considered distant metastasis 
and designated as M1A. For tumors located in the upper thoracic oesophagus 
metastases to cervical lymph nodes also carry the designation M1A. Any other 
lymph nodes involved by tumor are classified with other distant sites of 
involvement as M1B. It has been recommended that lymph node status be based on 
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examination of at least 6 lymph nodes in the resected specimen; however, one 
analysis noted an improvement in sensitivity to over 90% when 12 or more lymph 
nodes were examined as is recommended for colorectal carcinoma.  
TABLE 4. Tumor (T), Node (N), Metastasis (M) Staging System for
oesophageal Cancer 
PRIMARY 
TUMOR (T) 
  
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor invades lumina propria or submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades adventitia 
T4 Tumor invades adjacent structures 
T staging of the oesophagus 
CT cannot delineate the component layers of the oesophageal 
wall and therefore is unable to differentiate between T1 and T2 
lesions. CT cannot detect microscopic invasion in T3 tumours 
and differentiating macroscopic T3 from focal tumour bulging 
or juxtalesional lymphadenopathy can be impossible, particularly 
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in cachectic individuals. Understaging is more common 
than over staging. CT findings suggesting T4 involvement of 
the aorta, tracheobronchial tree, and crura are well documented 
but the signs are “soft” leading to poor sensitivity 
when compared with EUS. However, CT can predict mediastinal 
invasion in over 80% of patients. 
REGIONAL 
LYMPH 
NODES (N) 
  
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 
N Ia 
N Ib 
N Ic 
Regional lymph node metastasis 
1-2 nodes  
 
2-4 nodes  
 
4-6 nodes  
 
 
N staging 
CT scanning 
Size is the only criterion for assessment of lymph nodes and is 
a poor predictor of involvement, particularly in the chest, 
where large nodes may be reactive. The accuracy of CT 
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diagnosis of mediastinal node involvement ranges from 38% 
to 70%. If nodes over 8 mm in diameter are considered abnormal 
in the coeliac axis, a sensitivity of 48% and a specificity of 
93% is achieved. Identification of more distant nodal groups 
is of particular importance as these nodal groups may not be 
amenable to evaluation with EUS and will often be outside the 
borders of even a radical resection. 
DISTANT 
METASTASIS 
(M) 
  
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
  Tumors of the lower thoracic oesophagus 
     M1a      Metastasis in celiac lymph nodes 
     M1b      Other distant metastasis 
  Tumors of the mid-thoracic oesophagus 
     M1a      Not applicable 
     M1b      Nonregional lymph nodes and/or other distant metastasis
  Tumors of the upper thoracic oesophagus 
     M1a      Metastasis in cervical lymph nodes 
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     M1b      Other distant metastasis 
M staging 
In a newly diagnosed oesophageal cancers 
revealed that 18% have metastases at presentation , 45% of 
metastases were in abdominal lymph nodes and 18% in cervical 
lymph nodes. In addition, 35% of metastases were hepatic, 
20% pulmonary, 9% bone, 5% adrenal, 2% peritoneal, and 2% 
cerebral. As all patients with bone and brain 
metastases were associated with metastatic disease in the 
abdomen and thorax, hence in the absence of clinical indications, 
evaluation of metastatic disease should be focused on 
examination of the thorax and abdomen. 
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TABLE.5  Classification of Stage Groupings for Oesophageal Cancer 
Stage Groupings TNM Classifications 
0 Tis N0 M0 
I T1 N0 M0 
IIA T2 N0 M0 
  T3 N0 M0 
IIB T1 N1 M0 
  T2 N1 M0 
III T3 N1 M0 
  T4 Any N M0 
IV Any T Any N M1 
IVA Any T Any N M1a
IVB Any T Any N M1b
 
Successive pathologically determined stage groups are predictive of length of 
survival. It has been suggested that extensive nodal disease may be associated with 
better survival than visceral metastases, and it does appear that survival with stage 
IVA disease more closely mimics that with stage III disease than that with stage 
IVB disease. 
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TREATMENT  
Optimal treatment of oesophageal cancer in every major stage grouping 
(premalignant or intramucosal lesions, localized resectable tumors, and unresectable 
metastatic disease) remains elusive and a work in progress that continues to 
engender substantial controversy. The paucity of appropriately designed studies to 
scientifically determine the most effective therapeutic strategy for any given clinical 
situation fuels the ongoing debate and undermines the potential for achieving 
consensus. Although there is no disagreement that oesophageal resection prevents 
progression from high-grade dysplasia to invasive carcinoma and is curative for T1 
lesions limited to the mucosa, the morbidity and mortality associated with 
oesophagectomy has created enthusiasm for alternative approaches such as mucosal 
ablation and endoscopic resection. Surgery has always been considered the most 
effective way of ensuring both local-regional control and long-term survival for 
patients with tumors invading into or beyond the submucosa with or without lymph 
node involvement. Some investigators suggest that extending the limits of resection 
will further improve outcome. However, surgery alone or any other single modality 
fails in the vast majority of patients, which has led many oncologists to embrace 
combined modality therapy and some to question the necessity for surgical 
intervention. Despite the lack of convincing evidence to support its use, 
chemoradiotherapy with or without resection is the most common therapeutic 
regimen offered to patients with oesophageal carcinoma in the United States. A full 
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understanding of these issues and others regarding the treatment of carcinoma of the 
oesophagus requires careful scrutiny of the available literature with an attempt to 
separate bias from fact in developing a rational therapeutic approach for patients 
regardless of the stage of their disease. 
TREATMENT OF PREMALIGNANT AND T1 DISEASE (LOCALIZED TO 
THE MUCOSA ONLY) 
Pathologic confirmation of high-grade dysplasia in Barrett's oesophagus is the most 
powerful predictor of subsequent invasive adenocarcinoma and therefore warrants 
instituting a therapeutic plan. The rationale for oesophagectomy is that resection 
completely eradicates the mucosa at risk, which prevents progression to invasive 
carcinoma. This approach is further supported by numerous surgical series reporting 
that, for patients with high-grade dysplasia who undergo oesophagectomy, 
previously unidentified invasive cancer is present in up to 40% of resected 
specimens.  Patients with superficial invasive tumors confined to the mucosa have 
little or no risk of lymph node metastases and are considered candidates for 
potentially less morbidity-producing resection methods. 
Ablative Methods 
The mechanism of action of all mucosal ablative techniques, including 
photodynamic therapy (PDT), laser ablation, and argon plasma coagulation, is 
destruction of the mucosal layer. The premise for managing high-grade dysplasia 
with endoscopic ablative therapy is that mucosal injury in an acid-controlled 
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environment eliminates the premalignant mucosa and resurfaces the oesophageal 
lining with regenerated squamous epithelium. 
Endoscopic Mucosal Resection 
Endoscopic mucosal resection (EMR) is a relatively recent addition to the 
endoscopic therapeutic options available for patients with either high-grade 
dysplasia or superficial oesophageal cancers. EMR technique involves the 
submucosal injection of fluid to lift and separate the lesion from the underlying 
muscular layer, which allows full resection and tissue retrieval for appropriate 
histologic examination. The complete remission rate in patients with less favorable 
lesions was 59%, which emphasizes the need to adhere to strict criteria to optimize 
disease eradication. This technique is feasible for treatment of high-grade dysplasia 
and carcinoma limited to the mucosa and provides an alternative to 
oesophagectomy, especially in those patients considered high risk for surgical 
intervention. 
Minimally Invasive oesophagectomy 
There is little debate that oesophageal resection is the most definitive intervention 
for eliminating high-grade dysplasia and is extremely effective treatment for 
carcinoma limited to the mucosa. However, the substantial morbidity and potential 
for mortality associated with oesophagectomy, even in the most experienced hands, 
has resulted in considerable controversy regarding its acceptance as optimal therapy 
in this setting. In an attempt to reduce morbidity and mortality while achieving an 
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equivalent oncologic outcome, minimally invasive techniques for oesophageal 
resection have been designed and are being investigated. A variety of minimally 
invasive approaches have been used for oesophagectomy, including laparoscopic, 
thoracoscopic, combined laparoscopic and thoracoscopic, and hand-assisted 
techniques 67,68,69,70. These procedures have been applied to the treatment of all 
stages of potentially resectable oesophageal cancer but would seem to be most 
applicable in the management of premalignant and early-stage disease. Median 
operative time was 7.5 hours, median length of hospital stay was 7 days, and a 30-
day perioperative mortality was zero. Median follow-up was 20 months, and a 3-
year survival of 90% was achieved in patients with either high-grade dysplasia or 
stage I disease.  
Refer. Fig. 13. Minimally invasive oesophagectomy
 
Refer. Fig. 14. Thorocoscopic view of oesophagus 
 
TREATMENT OF LOCALIZED DISEASE 
Surgery has traditionally been the treatment of choice for patients with localized, 
resectable carcinoma of the oesophagus and continues to be a component of a more 
comprehensive approach to oesophageal cancer in a substantial number of patients. 
Failure of surgery alone to significantly alter the natural history of oesophageal 
cancer has resulted in considerable enthusiasm for combined modality therapy. The 
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shift toward multimodal treatment, although theoretically sound, is not convincingly 
supported by data from phase III clinical trials comparing preoperative therapeutic 
regimens (radiation, chemotherapy, or chemoradiotherapy) to surgery alone. 
Similarly, although it is appropriate to question the role of surgery in a multimodal 
approach to treatment of oesophageal cancer, no data are currently available from 
studies designed to examine the necessity of surgery, and therefore the wisdom of 
eliminating resection from the treatment algorithm is questionable.  
 
Surgical Resection 
Many controversies exist regarding the surgical treatment of oesophageal cancer, 
including the optimal surgical approach, the extent of local resection and lymph 
node retrieval, selection of a reconstructive conduit, and location of the 
anastomosis. Decisions regarding surgical technique are routinely based from 
personal bias, comfort level of the surgeon, and a subjective view of tumor biology, 
because solid evidence from scientifically designed trials is marginal and, in most 
instances, nonexistent. However, there is a growing body of evidence which 
suggests that outcome after oesophagectomy is directly related to both surgeon and 
hospital volume. Numerous studies that used health services linked databases have 
demonstrated a statistically significant association between performance of surgery 
in hospitals designated as high-volume oesophagectomy institutions and lower 
complication and mortality rates.71,72,73,74. Although this link has been shown for 
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other complex surgical procedures, the association between volume and outcome 
for oesophageal resection appears to be one of the strongest.  
 
TRANSHIATAL OESOPHAGECTOMY. The transhiatal route for oesophageal 
resection has gained favor, especially among surgeons in the developed countries , 
concurrent with the rising incidence of adenocarcinoma of the distal oesophagus, 
which is readily approachable and effectively dissected through the diaphragmatic 
hiatus .  It is prudent to initially perform laparoscopic exploration to rule out 
disseminated disease and, if it is confirmed, to abort the intended resection before 
exposing the patient to the risks of laparotomy. Through a midline incision, the 
stomach is mobilized by dividing all vascular attachments while preserving the right 
gastroepiploic and right gastric vessels on whose pedicle the reconstructive conduit 
will be based. The duodenum is fully mobilized via a Kocher maneuver and a 
pyloric drainage procedure is performed, which has been demonstrated in 
prospective randomized trials to reduce gastric stasis and minimize pulmonary 
complications such as aspiration.75,76 Cautery division of the diaphragmatic crus 
allows wide access to the mediastinum and dissection under direct vision of the 
middle and lower third of the oesophagus. A left cervical incision provides 
exposure to the cervical oesophagus, and circumferential dissection of the cervical 
oesophagus is carried down to below the thoracic inlet to the upper thoracic 
oesophagus, with care to avoid injury to the recurrent laryngeal nerve. The 
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remainder of the dissection at the level of and superior to the carina is completed by 
blunt dissection through the oesophageal hiatus. The cervical oesophagus is then 
divided, the stomach and attached intrathoracic oesophagus are delivered through 
the abdominal wound, and a gastric tube, which will serve as the reconstructive 
conduit, is fashioned using multiple applications of a linear stapling device. The 
gastric tube is then transposed through the posterior mediastinum to the cervical 
wound, where a cervical oesophagogastric anastomosis is performed. The stomach 
is considered by most surgeons as the replacement conduit of choice for the 
resected oesophagus. A segment of colon, usually based on the ascending branch of 
the inferior mesenteric artery, is an effective oesophageal substitute if for any 
reason the stomach is deemed unsuitable for reconstruction or the surgeon prefers. 
Although the original intent of this approach was not to perform a methodical 
lymph node dissection, a standard two-field lymphadenectomy (abdominal and 
lower mediastinal) can readily be achieved, and for that matter, if the surgeon is so 
inclined, a radical en bloc resection can be performed  
 
Refer. Fig. 15. Trans-hiatal surgery. 
TABLE.6   Conventional Approaches to Oesophageal Resection for Cancer
TRANSHIATAL 
Laparotomy and cervical approach 
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Peritumoral or two-field lymph node dissection 
En bloc resection feasible for distal Oesophageal tumors 
Cervical anastomosis 
TRANSTHORACIC 
Ivor Lewis 
Right thoracotomy and laparotomy 
Peritumoral or two-field lymph node dissection 
En bloc resection feasible for mid-/distal thoracic tumors 
McKeown Oesophagectomy 
Right thoracotomy, laparotomy, cervical approach 
Peritumoral, two-field or three-field lymph node dissection
En bloc resection feasible for mid-/distal thoracic tumors 
Cervical anastomosis 
Left thoracotomy 
Left thoracotomy with or without cervical approach 
Peritumoral lymph nodes dissection 
Intrathoracic or cervical anastomosis 
Left thoracoabdominal 
Left thoracoabdominal approach 
Peritumoral or two-field lymph node dissection 
Intrathoracic anastomosis 
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The stated advantages attributed to the transhiatal approach to oesophagectomy 
include avoidance of a thoracotomy incision, which thereby minimizes pain and 
subsequent postoperative pulmonary complications; elimination of the lethal 
complications of mediastinitis associated with an intrathoracic anastomotic leak; 
and a shorter duration of operation, which results in decreased morbidity and 
mortality. Limitations and disadvantages of transhiatal oesophagectomy include 
poor visualization of upper and mid-thoracic oesophageal tumors, increased 
anastomotic leak rate with subsequent stricture formation, possibility of 
chylothorax, and possibility of recurrent laryngeal nerve injury. The largest 
experience with transhiatal oesophagectomy was reported by Orringer et al. and 
included 800 patients with oesophageal cancer, 69% of whom had adenocarcinoma 
and 28% of whom had squamous cell carcinoma. Tumors were located in the lower 
third of the oesophagus in 74.5%, in the middle third in 22%, and in the upper third 
in 4.5%. In-hospital mortality was 4.5%. The most common complications were 
anastomotic leak (13%) and recurrent laryngeal nerve palsy (7%). Leak of a 
cervical oesophageal gastric anastomosis was handled simply in the vast majority of 
patients with opening of the cervical wound, followed by local wound care. 
Hoarseness from recurrent laryngeal nerve injury resolved spontaneously in 99% of 
cases. Overall 5-year survival was 23%, and stage-specific 5-year survival was 59% 
for stage I, 22% for stage II, 29% for stage IIB, and 10% for stage III. These results 
reflect those reported from other surgical series of transhiatal oesophagectomy  
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TABLE.7  Results of Transhiatal Oesophagectomy for Oesophageal Cancer 
Study Year Patients 
(n) 
Histologic 
Type 
Perioperative 
Mortality (%) 
5-Y Survival 
(%) 
Gelfand et al.  1992 160 A 0.9 21 
Gertsch et al.  1993 100 A/S 3 23 
Vigneswaran et
al.  
1993 131 A/S 2.3 21 
Dudhat and
Shinde 
1998 80 S 7.5 37 
Orringer et al.  1999 800 A/S 4.5 23 
Bolton and Teng 2002 124 A/S 1.6 27.3 
A, adenocarcinoma; S, squamous cell carcinoma. 
 
TRANSTHORACIC OESOPHAGECTOMY. Transthoracic oesophagectomy 
has been the most common surgical approach used to resect carcinomas of the 
oesophagus Although a left thoracotomy provides adequate exposure to tumors of 
the distal oesophagus, a right thoracotomy affords access to upper, mid-, and distal 
42 
 
oesophageal lesions and is the preferred route for transthoracic exposure. A right 
thoracotomy combined with an upper midline laparotomy (Ivor Lewis 
oesophagectomy) is the technique most commonly used for oesophageal resection 
and is briefly described here. The abdominal portion of the procedure duplicates 
that of the transhiatal approach detailed earlier in Transhiatal Oesophagectomy and 
includes mobilization of the stomach and distal oesophagus, upper abdominal 
lymphadenectomy, pyloromyotomy, and placement of a feeding jejunostomy before 
abdominal wound closure and repositioning for the thoracic component of the 
procedure. A muscle-sparing right lateral thoracotomy is performed through the 
fifth or sixth intercostal space. The azygos vein is divided, the mediastinal pleura 
incised, the intrathoracic oesophagus mobilized, and a mediastinal lymph node 
dissection performed. After  division of the proximal oesophagus in the chest 
ensuring an adequate margin, the gastro oesophageal junction and stomach are 
pulled into the thoracic cavity. The stomach is then divided with a linear stapler, the 
specimen is removed and an oesophagogastric anastomosis performed. An 
alternative approach has been described in which the right thoracotomy is the initial 
stage of the procedure followed by repositioning of the patient supine for an 
abdominal and left cervical incision to achieve a cervical oesophagogastric 
anastomosis.84,85 
The transthoracic approach provides direct visualization and exposure of the 
intrathoracic oesophagus facilitating a wider dissection to achieve a more adequate 
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radial margin around the primary tumor and more thorough lymph node dissection, 
which theoretically results in a more sound cancer operation. In patients with 
significant comorbid conditions, the combined effects of an abdominal and thoracic 
incision may compromise cardiorespiratory function. An intrathoracic anastomotic 
leak can lead to mediastinitis, sepsis, and death. In addition, oesophagitis in the 
nonresected thoracic oesophagus may occur secondary to bile reflux. The three-
incision (cervical, thoracic, and abdominal) modification of the procedure 
effectively eliminates the potential for complications associated with an 
intrathoracic oesophagogastric anastomosis. 
Numerous authors have reported results of transthoracic oesophagectomy; however, 
most, if not all, of these reports include patients who were resected via other 
surgical approaches and underwent a more extended lymphadenectomy. 
93,94,95,96,97,98 . Suffice it to say that both overall and stage-specific 5-year 
survival rates were similar to those seen with transhiatal oesophagectomy. The 
cleanest data may be derived from prospective randomized trials exploring the role 
of induction therapy before oesophagectomy in which there is a surgery-alone 
control arm. In only one of those trials, that conducted by Bossett et al.,96 was a 
transthoracic approach the only surgical procedure allowed. In that trial, 139 
patients were randomly assigned to the surgery-alone group. Median survival time 
was 18.6 months and 5-year survival rate was 26%. 
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TABLE .8 . Results of Transthoracic Oesophagectomy for Oesophageal Cancer
Study Year Patients 
(n) 
Histologic 
Type 
Perioperative 
Mortality (%) 
5-Y Survival 
(%) 
Wang et al.284 1992 368 S 6.5 7.6 
Lieberman et
al.285 
1995 258 A/S 5 27 
Adam et al.283 1996 597 A/S 6.9 16.3 
Sharpe and
Moghissi281 
1996 562 A/S 9 18 
Bossett et al.286 1997 139 S 3.6 26 
Ellis282 1999 455 A/S 3.3 24.7 
A, adenocarcinoma; S, squamous cell carcinoma. 
 
TRANSHIATAL VERSUS TRANSTHORACIC OESOPHAGECTOMY. The 
controversy regarding the optimal surgical approach for oesophageal cancer 
remains unresolved. Proponents of transthoracic oesophagectomy claim superior 
oncologic outcome secondary to wider tumor clearance and more thorough 
lymphadenectomy. Supporters of transhiatal oesophagectomy argue that a 
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cervicoabdominal approach minimizes postoperative morbidity and mortality and is 
oncologically equivalent to the transthoracic approach. 
Two large metaanalyses have compared transhiatal oesophagectomy to 
transthoracic oesophagectomy based on collective reviews of numerous individual 
studies.Both reports include studies that compared transhiatal to transthoracic 
oesophagectomy, studies of transhiatal oesophagectomy only, and studies of 
transthoracic oesophagectomy only. The vast majority of these studies were 
retrospective and were not standardized with regard to techniques used, use of 
additional therapy, and results reporting. The collective review by Rindani et al. 
encompassed 5483 patients from 44 series published between 1986 and 1996. 
Perioperative mortality was significantly higher in the transthoracic 
oesophagectomy group than in the transhiatal group (9.5% vs. 6.3%), whereas 
overall perioperative complications were not significantly different in the two 
groups. Patients who underwent transhiatal oesophagectomy had a higher incidence 
of anastomotic leak, anastomotic stricture, and recurrent laryngeal nerve injury. 
Overall 5-year survival was similar for the two groups: 24% for the transhiatal 
oesophagectomy group and 26% for the transthoracic oesophagectomy group. 
Hulscher et al.98 performed a collective review of 50 studies performed between 
1990 and 1999 yielding 7527 patients for comparison of the transthoracic versus the 
transhiatal route. Postoperative mortality was significantly greater in the 
transthoracic group than in transhiatal group (9.2% vs. 5.7%). Transthoracic 
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oesophagectomy was associated with a significantly higher risk of pulmonary 
complications (18.7% vs. 12.7%), whereas patients treated with transhiatal 
oesophagectomy had a higher anastomotic leak rate (13.6% vs. 7.2%). Five-year 
survival was not significantly different, with 23% 5-year survival for transthoracic 
oesophagectomy and 21.7% 5-year survival with transhiatal oesophagectomy. A 
prospective database based on the Veterans Administration National Surgical 
Quality Improvement Program was used to analyze perioperative outcome in 945 
patients, 562 who underwent transthoracic oesophagectomy and 383 who 
underwent resection through a transhiatal approach. There was no difference in 
overall mortality (10% for transthoracic approach vs. 9.9% for transhiatal approach) 
or morbidity (47% for transthoracic vs. 49% for transhiatal). 
Four phase III trials have prospectively examined the outcomes for patients 
randomly assigned to undergo either transhiatal or transthoracic oesophagectomy. 
No definitive conclusions can be drawn from three of these trials due to the 
extremely small sample size. The trial in the Netherlands, however, deserves special 
attention. Hulscher et al. randomly assigned 220 patients with mid- or distal 
oesophageal carcinoma to undergo either transhiatal esophagectomy or 
transthoracic esophagectomy. The transthoracic group underwent a systematic 
mediastinal and upper abdominal lymph node dissection. Although the number of 
lymph nodes retrieved was significantly higher in the transthoracic group (31 vs. 
16; P <.001), there was no difference in the radicality of the two procedures with 
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equivalent R0, R1, and R2 resections. Postoperative pulmonary complications, 
ventilatory time, intensive care unit stay, and hospital stay were significantly higher 
in those patients assigned to the transthoracic group. Despite the higher 
perioperative morbidity, there was no statistically significant increase in in-hospital 
mortality (4% vs. 2% for transthoracic vs. transhiatal oesophagectomy, respectively; 
P <.5). At a median follow-up of 4.7 years, there were no significant differences 
between the transhiatal and transthoracic oesophagectomy groups with respect to 
median disease-free interval (1.4 vs. 1.7 years, respectively) and median overall 
survival time (1.8 vs. 2.0 years, respectively). Likewise, no significant differences 
were noted in local-regional recurrence, distant recurrence, and combined local-
regional and distant recurrence for patients randomly allocated to the transthoracic 
or transhiatal oesophagectomy arm. The investigators point out that a trend toward 
improved disease-free survival (39% vs. 27%) and overall survival (39% vs. 29%) 
at 5 years favored the transthoracic approach group. 
From the data presented, one could reasonably conclude that either the transhiatal or 
transthoracic procedure can be performed with acceptable morbidity and mortality 
in experienced hands and that, with either technique, the outcome is remarkably 
similar that is, poor. 
 
 
48 
 
COMPARISON OF DEFINITIVE CHEMORADIATION AND SURGERY. 
Although there are a number of trials comparing preoperative chemoradiation with 
surgery alone, there is no trial that directly compares the two standard treatments for 
nonmetastatic oesophageal cancer: nonoperative chemoradiation and surgery alone. 
It is an important issue for the practicing oncologist and for the establishment of 
standards of care. The positive results of RTOG 85-01, demonstrating a 27% 5-year 
survival rate for patients treated with definitive chemoradiation compared with no 
5-year survival after treatment with radiotherapy alone, is a major advance. This 
treatment option has influenced the selection of patients for nonsurgical 
management because it provides an alternative for restoring swallowing function in 
patients with locally advanced disease for whom resection would likely be 
palliative. 
For patients with earlier-stage disease that appears resectable, definitive 
chemoradiation may also be appropriate treatment; however, prospective trials 
comparing this approach with surgery, stratified by stage, have yet to be performed. 
Nonetheless, contemporary series suggest that the nonsurgical approach offers a 
survival rate that is the same or better than that achievable with surgery alone. For 
example, the median survival time and 5-year survival rate were 14 months and 
27%, respectively, in the chemoradiation arm of RTOG 85-01 and 20 months and 
20%, respectively, in INT 0122.394 In comparison, the median survival in the 
surgical control arm of the Dutch trial reported by Kok et al.306 was 11 months, 
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and the median survival time and 5-year survival rate in the surgical control arm of 
INT 0113 were 16 months and 20%, respectively. Likewise, the local failure rates 
were similar. The incidence of local failure (local recurrence plus local persistence 
of disease) as the first site of failure was 45% in RTOG 85-01 and 39% in INT 
0122. Although local failure as the first site of failure was 31% in INT 0113, this 
analysis was limited to patients who underwent a complete resection with negative 
margins (R0 resection). Because an additional 30% of patients had residual local 
disease, if one were to score these patients also as having locally persistent disease 
(as was done in the RTOG 85-01 analysis), the comparable local failure rate with 
surgery alone would be 30% + 31% = 61%. The treatment-related mortality rates 
were also similar (2% in RTOG 85-01, 9% in INT 0122, and 6% in INT 0113). 
In summary, the local failure, survival, and treatment-related mortality rates for 
nonsurgical and surgical therapies are similar. Although the results are comparable, 
it is clear that both the nonsurgical and surgical approaches have limited success. 
Refer. Table. 9. Surgery vs chemoradiation. 
NECESSITY FOR SURGERY AFTER CHEMORADIATION. Two trials 
examine whether surgery is necessary after chemoradiation. The Federation 
Francaise de Cancerologie Digestive (FFCD) trial addresses the issue of whether 
patients who respond midway through chemoradiation should continue with the 
treatment or undergo surgery.The German Oesophageal Cancer Study Group 
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examined the question of whether chemoradiation followed by surgery is equivalent 
to nonoperative chemoradiation. 
In the FFCD 9102 trial, all 445 patients with clinically resectable T3 to 4 N0 to 1 
M0 squamous cell carcinoma or adenocarcinoma of the oesophagus received 
chemoradiation; however, the randomization was limited to patients who responded 
to initial chemoradiation. Patients initially received two cycles of 5-FU and cisplatin 
plus concurrent radiation (either 46 Gy at 2 Gy/d or a split-course regimen of 15 Gy 
in weeks 1 and 3). The 259 patients who had at least a partial response were then 
randomly assigned to receive surgery or additional chemoradiation, which included 
three cycles of 5-FU and cisplatin, plus concurrent radiation (either 20 Gy at 2 Gy/d 
or split-course 15 Gy). There was no significant difference in 2-year survival (34% 
for those undergoing surgery vs. 40% for those receiving chemoradiation; P = .56) 
or median survival (18 months for the surgery group vs. 19 months for the 
chemoradiation group). The data suggest that patients who initially respond to 
nonoperative chemoradiation should complete chemoradiation rather than stop and 
undergo surgery. As measured using the Spitzer index, there was no difference in 
global quality of life; however, a significantly greater decrease in quality of life was 
observed in the postoperative period in the surgery arm (7.52 vs. 8.45; P <.01).  
The German Oesophageal Cancer Study Group compared preoperative 
chemoradiation followed by surgery with chemoradiation alone. In this trial, 177 
patients with T3N0M0 squamous cell cancers of the oesophagus were randomly 
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assigned to receive preoperative therapy (three cycles of 5-FU, leucovorin, 
etoposide, and cisplatin, followed by concurrent etoposide and cisplatin, plus 40 Gy 
of radiation) followed by surgery or chemoradiation alone (the same chemotherapy 
regimen, but the radiation dose was increased to 60 Gy). Despite an improvement in 
local control for those who were randomly assigned to receive preoperative therapy 
followed by surgery compared with those receiving chemoradiation alone (81% vs. 
64%), there was no significant difference in 3-year survival (28% vs. 20%). 
Although the difference in the radiation dose in the two arms makes the 
interpretation of the data difficult, there does not appear to be a benefit to surgery 
after nonoperative chemoradiation.  
STAGE-DIRECTED TREATMENT RECOMMENDATIONS  
Although, in many clinical situations, level I evidence is lacking to support ironclad 
recommendations regarding the most effective treatment of patients grouped by 
stage, reasonable trial-generated information exists to suggest appropriate 
therapeutic interventions for patients catalogued under broad staging categories. 
Resection remains the standard by which all other treatment options must be 
measured for patients with high-grade dysplasia in the setting of Barrett's 
oesophagus or T1 disease limited to the mucosa with the caveat that 
esophagectomy-associated mortality must be extremely low. With more experience 
and longer follow-up data, ablative methods or the more attractive therapeutic 
option, EMR, may become universally accepted as treatment alternatives 
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considered comparable to surgery. Intensive long-term endoscopic surveillance for 
patients with Barrett's oesophagus associated high-grade dysplasia is necessary to 
limit both cancer- and treatment-related mortality. 
Esophagectomy is an appropriate method for treating patients with stage I, II, III, 
and select IVA disease. Alternatively, definitive chemoradiation is a therapeutic 
option for patients with stage II and III disease and the majority of those with stage 
IVA lesions, especially those who are not considered surgical candidates or who 
have squamous cell carcinoma at or above the carina. The high rate of persistent or 
recurrent local-regional disease after definitive chemoradiation suggests that 
additional local therapy in the form of surgery may be necessary and beneficial. 
This potential benefit may only be realized if perioperative mortality is minimized. 
Although preoperative chemoradiotherapy has not been definitively proven to be 
more effective than surgery alone, it remains an attractive approach that has been 
embraced by oncologists for patients with resectable stage IIB, III, and selected 
IVA oesophageal cancers and should continue to be examined in well-designed 
clinical trials. Postoperative chemoradiotherapy should be reserved for patients with 
resected adenocarcinoma of the gastrooesophageal junction. All patients with 
unresectable or stage IV disease are ideally suited for clinical trials exploring novel 
therapeutic agents and approaches. 
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AIMS AND OBJECTIVES 
 
 Cancer oesophagus, is such surgery dependant disease, since surgery is used 
in investigational, curative and palliative purposes. To outline the various types of 
surgery done in the management of carcinoma oesophagus- a prospective study 
summarizing the effectiveness of various surgery with response to survival, 
particularly Trans Hiatal oesophagectomy versus Trans Thoracic oesophagectomy 
was studied. 
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MATERIALS AND METHODS 
A prospective analysis of cancer oesophagus patients treated at Department of 
Surgery and Surgical oncology between 2010-2011 in our institutions are taken into 
study. 
Patient Selection: All Patients who attend surgery OPD  in hospital and found to 
have Carcinoma oesophagus in the OGD and who do not have any other associated 
upper G.I pathology.  Radical surgery  recommended for patients with localised 
(T1, T2) tumours who are sufficiently fit to tolerate the procedure. 
Criteria for Inclusion in the study: 
1) patients  age >12 years and < 65 yrs. 
2) Has underwent OGD scopy. 
3) Histologically proven carcinoma. 
4) Performance status 1-2. 
Criteria for exclusion:  
1) patients < 12 years of age >65 yrs of age.  
Data collection: By direct interview of the patients/relatives and by OGD, biopsy, 
CT scan of the chest/abdomen. 
Methods 
Protocol on arrival: patients were examined in detail in the ward along with OGD 
and biopsy and coexistent medical conditions. 
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Investigations:  
 Complete hemogram 
 Urine routine 
 Blood glucose profile, renal function tests, liver function tests and 
electrolytes 
 Chest x-ray 
 ECG in all leads. 
 HIV BY ELISA 
 Upper GI endoscopy(flexible) with biopsy report 
 CT SCAN abdomen and chest. 
ETHICAL CLEARANCE OBTAINED : Ref.No. 15806/E4/2010   
. 
Consent forms: obtained from all patients included in the study. 
 
Statistical Analysis: prospective analysis. 
 
Conflict of Interest:Nil 
 
Financial support: Nil 
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OBSERVATION AND RESULTS 
During the period of study there were 27 cases of cancer oesophagus  admitted  in 
various surgery units and speciality wards. Of these 18 were squamous cell 
carcinoma(SCC) and  9 were adenocarcinoma(ACA). Due to non availability of 
ENDOSCOPIC USG , we did  OGD scopy with biopsy and  CT chest/abdomen , 
combined by which 12(all were SCC) were found to be middle third ,10(9 were 
ACA and 1 SCC) found in lower third  and 5 (all were SCC) in the upper third 
approximately. 
By preparing the patient for surgery and assessing them, we could perform 14 trans 
hiatal(THS) and 8 trans thoracic surgeries(TTS). Rest of the patients(five) who were 
found to operable by CT SCAN were found to be locally advanced and non-
resectable and in upper one third lesions hence refered to referred to 
chemo/radiation units(stage migration).  Of the total 22 defnitive surgeries 
performed 3/14 patients in THS arm(21.4% mortality) died post-operatively and 3/8 
patients in TTS arm(37.5% mortality) died in post-op. Both the arm patients 
required more than 14 days stay in hospital with particular TTS patients requiring 
post operative ventilators in most of the patients. There were no reports of 
anastomotic leakage in all 5 patients in TTS arm , one patient had prolonged fever 
for more than 10 days in THS arm which subsided after full survey. 4/11  patients 
had cervical anastomotic leak in THS arm, but all of healed by self in the next 21 
days. We could not do BARIUM SWALLOW for all our patients who underwent 
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definitive surgery as  few  were  lost to our follow up. In THS arm  all 11 patients 
were relieved of dysphagia to a major extent, the oesophago-gastric anastomotic site 
by barium swallow done after 4 weeks in the TTS arm was found to adequate in 2/5 
patients.  
Follow-up upto a year was possible in 13/16 patients, as 3 patients were lost to 
follow up (2 in THS and 1 TTS 3/9 patients who developed local recurrence were 
referred to chemo/radiation units in THS arm and one developed distant metastasis 
and all 4 patients in TTS arm were found to be disease free upto 1 year.  
 
Refer. Table. 10. TTS versus THS – a comparison  
 Mortality rates were although higher in TTS arm, but they were not 
statistically significant(p>.01). 
 Incidence of anastomotic leak was significantly higher in THS arm(p<.01), 
even though they are self-limiting. 
 Anastomotic stricture were although seen in TTS arm, they required just 
endoscopic dilation in most of the patients . 
 THS arm patients developed significant local/distal recurrence as patients 
were not properly selected due to  non availability of ENDOSCOPIC USG 
( Endoscopic USG is sensitive in detecting T3 from T4 )  . 
 Patients in TTS arm were disease-free upto 1 year of follow, signifying 
TTS is a better surgery from oncological point of view.   
58 
 
 All the patients were alived up to 1 year of follow up.   
 Disease free survival up to 1 year  in the study was 77% ( 10/13) 
 
Refer.      Table. 11.- Post – operative complications 
Hence the morbidity due to TTS was weighed before disease free survival, it was 
found that with proper patient selection, vigourous respiratory exercise 
preoperatively , good intensive respiratory units, by  adding  scopy to the  
thoracotomy component and using staplers for anastomosis  we  can perform Trans 
Thoracic Surgery better with least morbidity and mortality. Trans Hiatal Surgery 
may be technically easier than Trans Thoracic surgery , but if patients are fit enough 
TTS can be attempted in an otherwise blind THS procedure since the mediastinal 
lymphadenectomy is not enough to be disease free.  All the previous literatures 
report equal morbidity and mortality in both surgeries, but the present one goes one 
step further by favouring TTS.   
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Table. 1 Trends in age-adjusted incidence rates for Oesophageal cancer in 
India.  
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RCT TRIAL OF SX VS 
SX+CHEMOTHERAPY
3 YR SURVIVAL NO. OF PTS OPERATIVE 
MORTALITY
SURVIVAL
NYGAARD et al 38 VS 34 13 VS 24 11 VS 18
WALSH et al 55 VS 58 2 VS 7 7 VS 3
BOSSET et al 139 VS 143 4 VS 13 41 VS 43
TOTAL 232 VS 235 5 VS 13 28 VS 37
 
Table. 2. Surgery vs surgery and chemotherapy showing increased mortality 
with increased survival in surgery and chemotherapy receiving patients. 
RCT TRIAL OF SX VS SX+ 
RADIOTHERAPY
5 YR 
SURVIVAL 
NO. OF PTS OPERATIVE 
MORTALITY
SURVIVAL
ARNOTTet al 86 vs 90 8 vs 10 16 vs 9
NYGAARD et al 50 vs 58 12 vs 12 10 vs 21
WANG et al 102 vs 104 5 vs 5 37 vs 33
LAUNOIS et al 57 vs 67 11 vs 13 11 vs 10
GIGNOUX et al 106 vs 102 18 vs 24 10 vs 9
TOTAL 401 vs 421 11 vs 13 18 vs 17
 
Table. 3. Surgery vs surgery and radiotherapy showing better survival and less 
mortality in surgery alone patients. 
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Table. 9. Surgery vs chemoradiation. 
 
Table. 10. TTS Versus THS – A Comparision  
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Table. 11. Post operative complications 
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Fig – 1  
 
Fig – 2 
64 
 
 
 
Fig 3. Anatomy of Oesophagus 
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Fig 4. Lymphatic drainage of Oesophagus 
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Fig. 5 Squamous cell carcinomas showing epithelisation, inter cellular  
bridges and cytokeratin 
 
Fig. 6. Adenocarcinoma 
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Fig. 7 Barium swallow study showing irregular tapering borders. 
 
                            
 
 
Fig -8: Chest X-ray 
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Fig -9 : Oesophagogram 
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Fig. 10. Upper oesophagogastroduodenoscopy showing irregular polypoidal 
lesions in various positions of oesophagus. 
 
 
 
Fig. 11 Endoscopic ultrasonogram showing five layers . 
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Fig. 12 video-assisted thorascopy (V.A.T) 
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Fig. 13. Minimally invasive Oesophagectomy 
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Fig. 14. Thorocoscopic view of Oesophagus 
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Fig. 15. Trans-hiatal surgery. 
 
Fig -16 : Single / Two / Three – Field Lymphadenectomy  
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DISCUSSION 
Selection of patients for surgery 
Twenty seven patients were selected for radical intervention  based on the stage and 
spread of the tumour and the general and specific medical fitness of the patient. A 
specialist surgeon cancer team in discussion with the patient and his/her family 
made treatment decisions. Patients for whom radical intervention is inappropriate 
(T4 tumours) may be best treated in local cancer units. However, the specialist 
surgeon cancer team supervises in developing an appropriate care plan for these 
patients . Combination therapy considered for T2 tumours. Similarly patients with 
only middle and lower one third oesophageal cancer were only included into the 
study. 
Choice of operative approach 
The histological tumour type, its location, and extent of the proposed 
lymphadenectomy determine the operative approach. Adequate mediastinal 
lymphadenectomy is done in SCC and extended to the abdomen in junctional ACA. 
We did not perform transhiatal oesophagectomy for SCC in lower one-third 
oesophageal cancers.. Since left thoracoabdominal approach is limited 
proximally by the aortic arch which may compromise the proximal limit of 
resection, tumours which lie at the level of the arch are difficult to deal with from 
the left side and this approach was avoided when the tumour lies at this level or 
higher. The most widely practised approach is the two phase Lewis-Tanner, with a 
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preliminary laparotomy and construction of a gastric tube and a right thoracotomy 
to excise the tumour and perform an oesophagogastric anastomosis at the apex of 
the mediastinum. A third cervical phase was  added in the case of proximally 
situated tumours in order to achieve the requisite degree of longitudinal clearance. 
 
All operations were done with particular attention  to the local tumour to minimise 
the risk of local recurrence and permit an adequate lymphadenectomy, which will 
reduce the risk of staging error. The extent to which lymphadenectomy per se 
minimises the risk of symptomatic local recurrence is not known, but there is 
evidence that more thorough lymphadenectomy is associated with better survival . 
Longitudinal submucosal spread is characteristic of all types of oesophageal 
carcinoma. Proximal extent of resection should ideally be 10 cm above the 
macroscopic tumour and 5 cm distal to it, when the oesophagus is in its 
radiotherapy natural state. Hence SCC of the upper one third lesions were given 
adjuvant radiotherapy. ACA of the lower oesophagus commonly infiltrates the 
gastric cardia, fundus, and lesser curve. Some degree of gastric excision is essential 
to accomplish an adequate lymphadenectomy in the abdomen and this should be 
created in such a way as to obtain a minimum distance of 5 cm beyond the distal 
extent of the macroscopic tumour . Most of these patients do not die from 
symptomatic locoregional recurrence. Adequate radial margins clearance were 
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given  and contiguous excision of the crura and diaphragm was considered, 
particularly for junctional tumours. 
Standards of lymphadenectomy 
The majority of patients who undergo surgery for either ACA or SCC of the 
oesophagus will have lymph node metastases. The principal aims of 
lymphadenectomy should be to minimise staging error, reduce locoregional risks of 
recurrence and, by increasing the number of patients undergoing an R0 resection, 
increase five year survival (R0 resection: complete macroscopic and microscopic 
clearance). In SCC, when a methodical approach to lymphadenectomy is applied, 
the numbers of lymph nodes involved are of prognostic significance  as is the ratio 
of invaded to removed nodes. Although there is considerable enthusiasm for the 
performance of lymphadenectomy in three fields (abdomen, thorax, and neck) in 
Japan, this approach has not been adopted . Abdominal single field node dissection 
involves dissection of the right and left cardiac node, the nodes along the lesser 
curvature, left gastric, hepatic, and splenic artery territories. Two field dissection 
additionally embraces thoracic lymphadenectomy and includes the para-aortic 
nodes along with the thoracic duct, para-oesophageal nodes, right and left 
pulmonary hilar nodes, those at the tracheal bifurcation. Three field dissection 
extends the lymphadenectomy to the neck to clear the brachiocephalic, deep lateral, 
and external cervical nodes, and the deep anterior cervical nodes adjacent to the 
recurrent laryngeal nerve chains in the neck. A number of studies have shown that 
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two field lymphadenectomy can be carried out without any significant increase in 
operative morbidity or mortality. Conversely, although the three field operation is 
advocated in Japan for SCC, its benefits may simply reflect the reduction in staging 
error, as nearly a quarter of all Japanese patients will have cervical lymph node 
metastases. There is no evidence that three field lymphadenectomy improves 
survival in patients with ACA and it must be accepted that the operation is 
associated with a higher risk of postoperative morbidity. 
 
Refer. Fig. 16. Single/Two/Three-field lymphadenectomy 
Choice of conduit, route, and anastomosis 
The commonest conduit is the stomach. The function of the intrathoracic stomach 
as an oesophageal replacement has been extensively studied. The necessary 
vagotomy can produce troublesome gastric paresis, hence we did pyloromyotomy. 
A prospective randomized trial suggested that the addition of a drainage procedure 
did not affect gastric emptying or clinical outcome although it was too small to 
reach statistical significance. Thus since the morbidity of pyloroplasty is small, its 
addition should be considered. Colon interposition is the next most suitable conduit 
when the stomach is not available. Again, functional performance has been studied 
in detail. Most surgeons favour a prevertebral route for reconstruction and this was 
shown to be superior to an anterior reconstruction in one randomised study although 
another small prospective randomised comparison with a retrosternal gastric tube 
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showed no differences in technical complications or functional outcome. The level 
at which the anastomosis is performed is the subject of continued debate. There are 
no randomised trials to compare subtotal oesophagectomy with anastomosis in the 
neck or oesophagogastrectomy with anastomosis in the superior mediastinum. Each 
has its proponents. Until and if such a trial is undertaken, the fundamental premise 
must be the presence of clear longitudinal resection margins and an acceptable 
morbidity and mortality. 
Both retrospective and prospective studies comparing manual versus mechanical 
oesophagogastric anastomosis have shown no difference in leak rates or other 
complications. Fewer strictures occur with handsewn anastomoses particularly 
single layer anastomoses. 
 
Postoperative management 
Meticulous attention to the maintenance of fluid balance and respiratory care were 
essential in the immediate postoperative period. Pain control and pulmonary 
physiotherapy are crucial. Although some authors advocate the routine use of a 
feeding jejunostomy, there have been no prospective trials to examine its value. 
Nearly all cases we did feeding jejunostomy, taking consideration into the 
nutritional built of our population. Early mobilisation is important in the prevention 
of venous thrombosis and pulmonary embolism. 
 
79 
 
SUMMARY AND CONCLUSION 
 Surgery was the only curative option for loco-regional disease (>20%) in 
western data & it is treatment of choice for T1 disease. In my study the loco 
regional control was 77% at 1 year and sugery can be considered as primary 
modality of treatment for disease up to T3 levels. But more number of 
patients and longer period of follow up in necessary to justifiy the results.     
 Preoperative radiation had no role in western setup in the stages II , III, IVA 
disesase . In our study as there was 25 % local recurrence pre operative 
radiotherapy may have a role as many of surgeries were trans-hiatal and 
histologically many were SCC.(lymph node metastasis is more common in 
SCC than in ACA.  
 Wherea as the comparison study of TTS and THS showed no conclusion in 
the available literature, in  my study Trans thoracic oesophagectomy was the 
standard surgical procedure against which any other surgery is compared and 
although its mortality  and morbidity are more than tran hiatal 
oesophagectomy , newer methods  of reducing its morbidity  and mortality 
can be safely adopted making it the best oncological  procedure and TTS can 
be even adopted for middle third  oesophageal cancer lesions . 
 Average disease free survival was 15-18 months with 25% loco-regional 
control in the western data whereas with the loco-regional control of 77% in 
my study patients can be expected to live longer . 
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 Taking consideration in tho the fact that SCC are more common in india in 
the middle third of oesophagus and lymph node metastasis are common TTS 
can be considered as the best oncological  surgery with extensive two – field 
lymphadenectomy exposure.      
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PROFORMA 
1. NAME: 
2. AGE: 
3. SEX: 
4. Inpatient No.: 
5. Unit /ward: 
6. Chief Complaints: 
7. O.G.D : 
8. CT SCAN REPORT: 
9. USG ABDOMEN: 
10. HISTOLOGICAL TYPE: 
11. SURGERY PERFORMED: 
12. POST-OPERATIVE EVENTS: 
13. ADJUVANT TREATMENT : 
14. NEO-ADJUVANT TREATMENT: 
15. FOLLOW-UP AFTER 4 WEEKS: 
16. FOLLOW-UP AFTER 1 YEAR: 
98 
 
17. MASTER CHART 
S.No  NAME  AGE/SEX Position of 
tumour in 
oesophagus 
SURGERY DEATH BARIUM 
SWALLOW-UP 4 
WKS 
FOLLOW-UP 1 YR 
1 Patinettampadi 40/M M 1/3 THS  YES YES 
2 Subramaniam 53/M M 1/3 THS   YES  YES 
3 Thangaraj 57/M L 1/3 Inoperable     
4 Panajavarnam 45/F L 1/3 TTS   NO YES 
5 Athiyadevar 30/M M 1/3 THS  DEAD    
6 Selvi 40/F M 1/3 THS   YES  NO 
7 Meena 49/F M 1/3 THS   YES  YES 
8 Gurusamy 62/M L 1/3 Inoperable    ‐ 
9 Adampatela 45/M L 1/3 TTS   NO YES 
10 Muthu 49/M M 1/3 THS  DEAD    
11 Packiyalaxmi 56/F L 1/3 TTS   YES  YES 
12 Muharkali 60/M M 1/3 THS   YES  YES 
13 Bose 56/M U 1/3 THS  DEAD    
14 Dhanasekaran 56/M L 1/3 TTS   NO NO 
15 Alexandar 30/M M 1/3 THS   YES  YES 
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16 Pungudi 51/M M 1/3 THS   YES  NO 
17 Gandi 42/M L 1/3 TTS  DEAD    
18 Suseela 40/F M 1/3 THS   YES  YES 
19 Rajendran 57/M U 1/3 Inoperable    ‐ 
20 Selvi 43/F M 1/3 THS   YES  YES 
21 Karupaih 42/M L 1/3 TTS  DEAD    
22 Pandi 55/M U 1/3 THS   YES  YES 
23 Pandiammal 31/F L 1/3 TTS   NO YES 
24 Alagu 62/F U 1/3 Inoperable    ‐ 
25 Vellaisamy 60/M M 1/3 THS   YES  YES 
26 Puspam 42/F L 1/3 TTS  DEAD   YES 
27 Alagiri 73/M U 1/3 Inoperable     
 
 
 
